News | December 12, 2022
Lupin launches generic version of Pennsaid in the US
Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of US $509 million in the US (IQVIA MAT October 2022)
Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of US $509 million in the US (IQVIA MAT October 2022)
Expressed happiness that more than 30 countries of the world have given recognition to Ayurveda as a traditional system of medicine
This one-of-a-kind ophthalmic subspecialty division is focused on the treatment of the eye condition glaucoma
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
The 9th World Ayurveda Congress and Arogya Expo 2022 aims to showcase the efficacy and strength of the AYUSH systems of medicine at the global level
The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies
Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
The plant, to be built in the Incheon Free Economic Zone in Songdo, Incheon, will be a facility for the manufacture of products such as sterile bags, cell culture media and membrane filters
Subscribe To Our Newsletter & Stay Updated
